Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases

被引:43
作者
Ruusalepp, Arno [1 ]
Czibik, Gabor
Flatebo, Torun
Vaage, Jarle
Valen, Guro
机构
[1] Tartu Univ Hosp, Dept Cardiac Surg, EE-51014 Tartu, Estonia
[2] Univ Oslo, Dept Physiol, Inst Basic Med Sci, Oslo, Norway
关键词
contractile function; infarction; ischemia; MAP kinase; nitric oxide;
D O I
10.1007/s00395-007-0644-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Hyperoxic exposure in vivo (> 95% oxygen) attenuates ischemia-reperfusion injury, but the signaling mechanisms of this cardioprotection are not fully determined. We studied a possible role of nitric oxide (NO) and mitogen activated protein kinases (MAPK) in hyperoxic protection. Methods Mice (n= 7 -9 in each group) were kept in normoxic or hyperoxic environments for 15 min prior to harvesting the heart and Langendorff perfusion with global ischemia (45 min) and reperfusion (60 min). Endpoints were cardiac function and infarct size. Additional hearts were collected to evaluate MAPK phosphorylation (immunoblot). The nitric oxide synthase inhibitor L-NAME, the ERK1/2 inhibitor PD98059 and the p38 MAPK inhibitor FR167653 were injected intraperitoneally before hyperoxia or normoxia. Results Hyperoxia improved postischemic functional recovery and reduced infarct size (p< 0.05). Hyperoxic exposure caused cardiac phosphorylation of the MAPK family members p38 and ERK1/2, but not JNK. L-NAME, PD98059 and FR167653 all reduced the protection afforded by hyperoxic exposure, but did not influence performance or infarction in hearts of normoxic mice. The hyperoxia-induced phosphorylation of ERK1/2 and p38 was reduced by L-NAME and both MAPK inhibitors. Conclusion Nitric oxide triggers hyperoxic protection, and ERK1/2 and p38 MAPK are involved in signaling of protection against ischemia-reperfusion injury.
引用
收藏
页码:318 / 326
页数:9
相关论文
共 35 条
  • [1] Protein kinase activation and myocardial ischemia/reperfusion injury
    Armstrong, SC
    [J]. CARDIOVASCULAR RESEARCH, 2004, 61 (03) : 427 - 436
  • [2] Phosphorylation state of hsp27 and p38 MAPK during preconditioning and protein phosphatase inhibitor protection of rabbit cardiomyocytes
    Armstrong, SC
    Delacey, M
    Ganote, CE
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (03) : 555 - 567
  • [3] Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium
    Baines, CP
    Goto, M
    Downey, JM
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1997, 29 (01) : 207 - 216
  • [4] Effect of nitric oxide on mitogen-activated protein kinases in neonatal pulmonary vascular smooth muscle
    Barman, SA
    [J]. LUNG, 2005, 183 (05) : 325 - 335
  • [5] Mammalian MAP kinase signalling cascades
    Chang, LF
    Karin, M
    [J]. NATURE, 2001, 410 (6824) : 37 - 40
  • [6] Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts
    Csonka, C
    Szilvássy, Z
    Fülöp, F
    Páli, T
    Blasig, IE
    Tosaki, A
    Schulz, R
    Ferdinandy, P
    [J]. CIRCULATION, 1999, 100 (22) : 2260 - 2266
  • [7] Role of nitric oxide in myocardial preconditioning
    Dawn, B
    Bolli, R
    [J]. NITRIC OXIDE: NOVEL ACTIONS, DELETERIOUS EFFECTS AND CLINICAL POTENTIAL, 2002, 962 : 18 - 41
  • [8] Ischemic preconditioning and lipopolysaccharide attenuate nuclear factor-κB activation and gene expression of inflammatory cytokines in the ischemia-reperfused rat heart
    Hiasa, G
    Hamada, M
    Ikeda, S
    Hiwada, K
    [J]. JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 2001, 65 (11): : 984 - 990
  • [9] Preconditioning protects the severely atherosclerotic mouse heart
    Li, GH
    Tokuno, S
    Tähepôld, P
    Vaage, J
    Löwbeer, C
    Valen, G
    [J]. ANNALS OF THORACIC SURGERY, 2001, 71 (04) : 1296 - 1303
  • [10] Comparison between ischaemic and anisomycin-induced preconditioning: Role of p38 MAPK
    Lochner, A
    Genade, S
    Hattingh, S
    Marais, E
    Huisamen, B
    Moolman, JA
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (03) : 217 - 230